CYC Signs Enterprise Agreement with UPHS
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The agreement includes immediate installations of Technegas® at two major hospitals and plans for additional sites over time. This partnership is significant for Cyclopharm's US expansion strategy, aiming to enhance revenue generation and clinical utilization of its products. The agreement is expected to drive recurring revenue through ongoing consumables and support fees associated with each installation.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Cyclopharm
- Preliminary Final Report
- Technegas US Footprint Expanding Across Four Regions
- Technegas Approved at the US National Institutes of Health
- Cyclopharm Capital Raising Investor Presentation
- Cyclopharm Successfully Completes A$14 million Placement
Later from Cyclopharm
- CYC Secures Multi-Site Agreement with Northwestern Medicine
- USA Technegas Expansion Update
- CYC First-Half 2026 Update
- Immediate 11-Site Technegas Rollout at University Hospitals
- New US Lung Imaging Guidelines Name Technegas as Preferred A
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm